Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

NCT04722029
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Adenovirus Specific T lymphocytes
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

Combined Effects of Early Behavioral Intervention and Propranolol on ASD

NCT02428205
View directory record Official record
Conditions
Autism
Interventions
Propranolol, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
3 Years to 10 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Terminated Not applicable Interventional

Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity

NCT02191501
View directory record Official record
Conditions
Obesity, Over Weight
Interventions
Pyloric restriction
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

NCT04458857
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Little Rock, Arkansas • Banning, California • Loma Linda, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

NCT00027365
View directory record Official record
Conditions
HIV Infections
Interventions
Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A, NefTat, AS02A Adjuvant, gp120W61D
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 30, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

NCT03316300
View directory record Official record
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
NT-501, Sham Procedure
Combination Product · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Recruiting Phase 1 Interventional

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

NCT07042100
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Dose level (DL)1, DL2, DL3, DL4, DL5
Biological
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Terminated Phase 1 Interventional

ITIL-306 in Advanced Solid Tumors

NCT05397093
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions
ITIL-306
Biological
Lead sponsor
Instil Bio
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

NCT01701024
View directory record Official record
Conditions
Acne
Interventions
ACYC, ACYC vehicle
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The P4 Intervention Study to Improve Adolescent Health

NCT02554682
View directory record Official record
Conditions
Adolescent Behavior
Interventions
Sexual Health, Alcohol Prevention, Teen Driving
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 17 Years
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

NCT03459287
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT, Control
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
11 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

NCT02433093
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Volunteer
Interventions
Basimglurant, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste

NCT02992314
View directory record Official record
Conditions
Medication Associated Metallic Taste , Dysgeusia
Interventions
Metaqil™ Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 4:12 PM EDT
Active, not recruiting Not applicable Interventional

Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)

NCT05649384
View directory record Official record
Conditions
Acute Chest Pain, NSTEMI - Non-ST Segment Elevation MI
Interventions
European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm, European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm
Diagnostic Test
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
64,374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT03954743
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Louisville, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 30, 2026, 4:12 PM EDT
Completed No phase listed Observational Results available

Adequacy and Efficacy of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique.

NCT00474968
View directory record Official record
Conditions
Colposcopy, Biopsy
Interventions
e2 Cell Collector [SoftPAP(R)], Spatula/Brush
Device
Lead sponsor
CytoCore, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Wellington, Florida • West Palm Beach, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

NCT00404274
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Warfarin oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 30, 2026, 4:12 PM EDT
Not yet recruiting Phase 2 Interventional

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Recruiting Phase 1 Interventional

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

NCT05687110
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Novobiocin Sodium
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Duarte, California • Irvine, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

Bone Conduction Auditory Performance Via the Tooth for Single-Sided Deafness

NCT00977314
View directory record Official record
Conditions
Unilateral Hearing Loss
Interventions
The Sonitus Bone Conduction Hearing System, SoundBite, SoundBite Hearing System
Device
Lead sponsor
Sonitus Medical Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Redwood City, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 30, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional

Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children

NCT05730491
View directory record Official record
Conditions
Irritable Bowel Syndrome, Abdominal Pain
Interventions
Social Learning and Cognitive Behavioral Therapy (SLCBT), Attention Education Control
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 30, 2026, 4:12 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Human Influenza Transmission Study Using Naturally Infected Community Donors

NCT07814495
View directory record Official record
Conditions
Influenza
Interventions
Influenza Donor Visit, Influenza Recipient Inpatient Exposures Sessions
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 4:12 PM EDT